Welcome to our dedicated page for MOBIX LABS SEC filings (Ticker: MOBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mobix Labs, Inc. filings document the public-company disclosures of a fabless semiconductor and connectivity company serving defense, aerospace, telecommunications and other high-reliability markets. Registration statements and prospectus materials cover Class A common stock offerings, resale registration matters and financial disclosures tied to its capital needs.
Material-event reports cover securities purchase agreements, a senior secured convertible promissory note, registration rights, the completed reverse stock split of Class A and Class B common stock, and related adjustments to equity plans and outstanding securities. Proxy and annual meeting filings describe director elections, stockholder voting matters, bylaw amendments, quorum requirements and other governance provisions.
Mobix Labs, Inc. launched an at-the-market program to sell up to $15.8 million of Class A Common Stock through Roth Capital Partners. Sales may occur from time to time under an ATM Sales Agreement, and Roth will be deemed an underwriter under the Securities Act.
The company will pay a 3.0% commission on gross proceeds and expects to use net proceeds for working capital. As of October 9, 2025, Class A shares outstanding were 58,624,989. The filing notes the company’s use of Form S-3 capacity and prior sales during the lookback period.
The risk disclosures highlight potential dilution from future issuances and note that entering into and selling under the ATM could prompt a dispute under a prior equity line agreement, which could lead to claims. Orders will be executed at company-imposed price limits with no escrow arrangement.
Mobix Labs, Inc. entered an at-the-market (ATM) offering agreement with Roth Capital Partners, allowing the company to sell, from time to time, up to $15.8 million of Class A common stock through Roth as sales agent. Sales will be made under Mobix’s effective Form S-3 (File No. 333-284351), declared effective on January 24, 2025, and a prospectus supplement filed on October 21, 2025.
Roth will receive a 3.0% commission on gross proceeds, and Mobix will reimburse specified expenses up to $75,000. The company intends to use net proceeds for working capital. The ATM permits sales using methods consistent with Rule 415(a)(4), including block and privately negotiated transactions.
Mobix Labs, Inc. (MOBX) reported an amended insider filing (Form 4/A) to correct the officer’s reported holdings. The amendment updates the directly held Class A common stock beneficially owned to 2,550,000 shares as of the prior filing date referenced.
The filing also lists indirect derivative holdings through the KSSF Trust tied to 125,000 shares of Class A. The Class B common stock is convertible into Class A at the holder’s option and will convert automatically upon a non‑permitted transfer or on the first trading day after the seventh anniversary of the December 21, 2023 closing date. The reporting person serves as President, CFO & Director.
Mobix Labs, Inc. (MOBX) insider filing: The Chief Executive Officer and Director reported an award of 1,000,000 Restricted Stock Units on September 19, 2025 at a price of $0.00. The RSUs are scheduled to vest in four equal 25% installments on January 1, 2027, April 1, 2027, July 1, 2027, and October 1, 2027. After this grant, the reporting person beneficially owns 2,035,885 shares of Class A common stock, held directly.
Mobix Labs, Inc. (MOBX) filed an amended Form S-1 registering the resale of up to 12,890,274 shares of Class A common stock by selling stockholders. The company is not selling any shares in this offering and will not receive proceeds from stockholder sales.
If outstanding warrants covered by this prospectus are exercised for cash, Mobix Labs states it would receive approximately $9.8 million in gross proceeds. The filing notes the registered shares would equal about 18% of outstanding Class A shares as of September 4, 2025, and that resales—or the perception of them—could pressure the trading price.
The prospectus also highlights recent financing activities. On September 3, 2025, a holder exercised 5,486,467 warrants for cash at $0.8202 per share, generating ~$4.5 million in gross proceeds, and received new inducement warrants for 8,229,701 shares at $1.08. On August 13, 2025, the company issued a $550,000 senior secured note convertible at $0.70 (up to 2,500,000 shares), with 150,000 commitment shares and caps including a 4.99% beneficial ownership limit and an exchange cap of 5,747,105 shares.
Bill Carpou, a director of MOBIX LABS, INC. (MOBX), reported equity changes dated 09/23/2025. The filing shows a grant of 46,855 Restricted Stock Units (RSUs) to the reporting person, increasing his direct beneficial ownership to 299,022 Class A common shares after the transaction. The report also discloses two fully vested stock options: one with an exercise price of $4.18 covering 20,000 shares (expiring 08/10/2030) and another with an exercise price of $6.84 covering 133,416 shares (expiring 04/04/2032). The form was signed on behalf of the reporting person by an attorney-in-fact on 09/25/2025.
Frederick C. Goerner, a director of Mobix Labs, Inc. (MOBX), reported multiple equity awards and holdings. On 09/23/2025 he was granted 46,855 Restricted Stock Units (RSUs) with a reported price of $0, bringing his reported beneficial ownership to 1,483,380 shares of Class A Common Stock (direct). The filing also shows fully vested, exercisable options to purchase 20,000 shares at $4.18 and 133,416 shares at $6.84. Additionally, the report lists 217,391 shares of Class B Common Stock convertible into Class A Common Stock; conversion occurs at the Reporting Person's option and will be automatic upon certain transfers or upon the first trading day after the seventh anniversary of the Closing Date. The Form 4 was signed by an attorney-in-fact on 09/25/2025.
Kurt Busch, a director of Mobix Labs, Inc. (MOBX), reported awards and existing holdings on a Form 4 dated with transactions on 09/23/2025. The filing shows 46,855 restricted stock units (RSUs) were granted to Mr. Busch on 09/23/2025, increasing his beneficial ownership to 372,429 shares of Class A common stock.
The report also lists two fully vested, exercisable stock options held directly by Mr. Busch: an option to buy 20,000 shares at an exercise price of $4.18 (expiration 08/10/2030) and an option to buy 133,416 shares at $6.84 (expiration 04/04/2032). The Form 4 was signed by an attorney-in-fact, Terri Aprati, on 09/25/2025.
Mobix Labs insider report: Director David J. Aldrich received 46,855 Restricted Stock Units on September 23, 2025 that will vest on October 1, 2025, and acquired the RSUs at no cash cost. Following that grant, he beneficially owns 289,744 shares of Class A common stock.
Derivative holdings: The filing discloses two fully vested, exercisable stock options: 20,000 options with a $4.18 exercise price (expiring 08/10/2030) and 133,416 options with a $6.84 exercise price (expiring 04/04/2032). The form was signed by an attorney-in-fact on September 25, 2025.
Mobix Labs insider ownership and awards disclosed in Schedule 13D. Keyvan Samini and related trusts report beneficial ownership of 3,316,733 shares of Class A common stock (including 125,000 Class B shares convertible into Class A), representing 5.6% of voting power based on the stated share counts. The filing describes acquisition of Class A shares, options and a grant of 2,550,000 restricted stock awards to Samini on May 5, 2025, which vest over two years and may accelerate at certain stock-price thresholds. Samini is President, CFO and a director of the issuer; employment agreements and multiple equity awards and RSUs are summarized and incorporated by reference.